Polpharma

Polpharma, established in 1935 and headquartered in Starogard Gdański, Poland, is a significant entity within the Pharmaceutical and Healthcare industries. The company specializes in the manufacturing of pharmaceuticals, active pharmaceutical ingredients (APIs), and various dosage forms, focusing on innovation, availability, and safety. With a substantial revenue of $1.5B, Polpharma demonstrates considerable market presence and operational scale. Its product portfolio encompasses generic drugs and active ingredients, serving critical healthcare needs across its operational regions. The company's commitment to quality is underscored by its extensive product development and manufacturing capabilities, positioning it as a key player in the European pharmaceutical landscape.

Operating with an employee range of 1,000-5,000 individuals, Polpharma manages a complex network of operations. The company's strategic focus includes expanding its reach and ensuring the accessibility of essential medicines. Its product development pipeline emphasizes both established generics and innovative solutions, aiming to meet diverse patient requirements. Polpharma's operational framework is designed for efficiency and compliance, reflecting its dedication to high standards in pharmaceutical production. For insights into its organizational structure and leadership, you can Meet Polpharma's team.

Polpharma's financial standing is robust, supported by significant revenue figures and strategic funding initiatives, including a notable debt financing round from the European Investment Bank. This financial backing enables continued investment in research, development, and manufacturing infrastructure. The company's market strategy involves navigating complex regulatory environments and competitive landscapes to ensure the consistent supply of high-quality pharmaceutical products. Further details on its financial performance and strategic investments are available via Explore financial highlights.